[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2441287C - Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees - Google Patents

Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees Download PDF

Info

Publication number
CA2441287C
CA2441287C CA2441287A CA2441287A CA2441287C CA 2441287 C CA2441287 C CA 2441287C CA 2441287 A CA2441287 A CA 2441287A CA 2441287 A CA2441287 A CA 2441287A CA 2441287 C CA2441287 C CA 2441287C
Authority
CA
Canada
Prior art keywords
cyanovirin
antiviral
protein
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2441287A
Other languages
English (en)
Other versions
CA2441287A1 (fr
Inventor
Michael R. Boyd
Barry R. O'keefe
Toshiyuki Mori
Angela M. Gronenborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/815,079 external-priority patent/US6780847B2/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2441287A1 publication Critical patent/CA2441287A1/fr
Application granted granted Critical
Publication of CA2441287C publication Critical patent/CA2441287C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte: sur une molécule isolée et purifiée d'acide nucléique codant pour une protéine ou pour un peptide comprenant au moins neuf acides nucléiques contigus de la SEQ ID NO:2, dont les acides nucléiques 30-32 de la SEQ ID NO:2 ayant été rendus résistants à la glycosylation, et dont au moins les neuf acides nucléiques contigus présentent une activité antivirale; sur un vecteur comportant ladite molécule; sur une cellule ou un organisme hôte comprenant ledit vecteur; sur un procédé d'obtention d'une protéine antivirale ou d'un peptide antiviral; sur la protéine antivirale ou le peptide antiviral ainsi obtenus; sur un conjugué comprenant la protéine antivirale ou le peptide antiviral; et sur des compositions comprenant une quantité efficace de la protéine antivirale, du peptide antiviral, du conjugué de protéine antivirale ou du conjugué de peptide antiviral. L'invention porte en outre sur un procédé prophylactique ou thérapeutique d'inhibition chez un hôte d'infections virales et spécifiquement de la grippe.
CA2441287A 2001-03-22 2002-03-22 Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees Expired - Fee Related CA2441287C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/815,079 2001-03-22
US09/815,079 US6780847B2 (en) 1995-04-27 2001-03-22 Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
PCT/US2002/009277 WO2002077189A2 (fr) 1995-04-27 2002-03-22 Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees

Publications (2)

Publication Number Publication Date
CA2441287A1 CA2441287A1 (fr) 2002-10-03
CA2441287C true CA2441287C (fr) 2014-06-10

Family

ID=29550490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2441287A Expired - Fee Related CA2441287C (fr) 2001-03-22 2002-03-22 Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees

Country Status (7)

Country Link
US (1) US7339037B2 (fr)
EP (1) EP1456382B1 (fr)
JP (1) JP4307841B2 (fr)
AT (1) ATE369427T1 (fr)
AU (1) AU2002254382B2 (fr)
CA (1) CA2441287C (fr)
DE (1) DE60221705T2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022303A2 (fr) * 2006-08-18 2008-02-21 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services activité antigrippe anti-H5N1 de la protéine antivirale cyanovirine
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019108656A1 (fr) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composition microbicide
CN111150724B (zh) * 2020-01-16 2020-12-22 华中农业大学 缬氨酸在制备治疗或预防禽流感病毒感染的药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470067A (en) 1967-09-19 1969-09-30 Pfizer & Co C Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes
US4795740A (en) 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
US5266478A (en) 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
DE3828842A1 (de) 1988-03-29 1989-10-12 Laube Hans Juergen Verfahren zur behandlung von rna und/oder dna
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
EP0470184B1 (fr) 1989-04-25 1997-02-12 Tanox Biosystems, Inc. Anticorps specifiques contre le domaine de liaison de cd4 du virus d'immunodeficience humaine
IE904161A1 (en) 1989-11-20 1991-05-22 Oncogen Nonreplicating recombinant-made retroviral particles useful¹as anti-viral agents and as immunogens for prophylaxis and¹therapy against human retroviruses
AU7160691A (en) 1989-12-21 1991-07-24 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes
SE9000333D0 (sv) 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
CA2082948C (fr) 1990-05-16 2000-07-11 Joseph G. Sodroski Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
JP2989862B2 (ja) 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
JPH06502539A (ja) 1990-10-26 1994-03-24 ザ・パブリック・ヘルス・リサーチ・インスティチュート・オブ・ザ・シティ・オブ・ニューヨーク・インコーポレーテッド Hiv−1 gp120のv3ループおよびcd−4結合部位に特異的な中和ヒトモノクローナル抗体
WO1992008983A1 (fr) 1990-11-19 1992-05-29 Queen's University At Kingston Marqueur de l'hiv/vaccin contre le sida
AU9053991A (en) 1990-11-20 1992-06-11 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
AU1538392A (en) 1991-03-11 1992-10-06 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
EP0503916A1 (fr) 1991-03-11 1992-09-16 Idec Pharmaceuticals Corporation Méthodes pour prélever des réactifs d'anticorps; anticorps d'anti-idiotype; et formulations de vaccin de sida
JPH0570493A (ja) 1991-05-31 1993-03-23 Chemo Sero Therapeut Res Inst ヒト免疫不全ウイルス(hiv)関連免疫調製物
AU685397B2 (en) 1991-08-22 1998-01-22 Nissin Shokuhin Kabushiki Kaisha Recombinant humanized anti-human immunodeficiency virus antibody
US5665569A (en) 1991-08-22 1997-09-09 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
EP0554446B1 (fr) 1991-08-22 1998-11-04 Nissin Shokuhin Kabushiki Kaisha Anticorps monoclonaux utiles dans la thérapie d'une infection à HIV-1
AU2752892A (en) 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
JPH08503121A (ja) 1991-12-10 1996-04-09 デイナ・フアーバー・キヤンサー・インステイテユート 中和反応性ヒト抗−gp120組換え抗体、それをコードするdnaおよびその使用
EP0581353A1 (fr) 1992-07-03 1994-02-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Anticorps monoclonaux dirigés contre HIV-1 gp120, lignées cellulaires les produisant et structures epitopiques correspondantes
ES2194015T3 (es) 1992-09-30 2003-11-16 Scripps Research Inst Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
AU7203194A (en) 1993-06-04 1995-01-03 New York University Bispecific human monoclonal antibodies specific for human immunodeficiency virus
NL9400384A (nl) 1994-03-11 1995-10-02 Smit Victor Retrovirus-vaccins, vaccinatie en immunotherapie tegen retrovirale infecties.
CA2124545A1 (fr) 1994-05-27 1995-11-28 Raoul E. Benveniste Methode d'induction d'une immunite a mediation cellulaire contre le virus vih utilisant de faibles doses d'immunogenes
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US6780847B2 (en) * 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6987096B1 (en) * 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US5891444A (en) 1995-06-07 1999-04-06 Virus Research Institute, Inc. HIV-1 prophylactic composition and method
WO1999019500A1 (fr) 1997-10-10 1999-04-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services Complexe de vecteur viral et de ligand biotinyles pour une fourniture de genes ciblee

Also Published As

Publication number Publication date
US20040220107A1 (en) 2004-11-04
EP1456382B1 (fr) 2007-08-08
EP1456382A4 (fr) 2004-12-22
DE60221705D1 (de) 2007-09-20
AU2002254382B2 (en) 2007-02-15
EP1456382A2 (fr) 2004-09-15
CA2441287A1 (fr) 2002-10-03
DE60221705T2 (de) 2008-06-05
JP2004535784A (ja) 2004-12-02
US7339037B2 (en) 2008-03-04
JP4307841B2 (ja) 2009-08-05
ATE369427T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
CA2364500C (fr) Conjugues de cyanovirine, cyanovirine fixee sur matrice, anticorps anti-cyanovirine, et compositions et procedes d'utilisation associes
AU707781B2 (en) Antiviral proteins, DNA coding sequences therefor, and uses thereof
US6780847B2 (en) Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6987096B1 (en) Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6193982B1 (en) Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
CA2441287C (fr) Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees
US5962668A (en) Nucleic acids encoding antiviral proteins and peptides fused to effector proteins
AU2002254382A1 (en) Glycosylation-resistant and nonglycosylated cyanovirins
US7048935B2 (en) Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
AU2003252207B2 (en) Cyanovirin conjugates, matrix -anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use
AU746809B2 (en) Antiviral proteins, DNA coding sequences therefor, and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170322